- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07680153
Neuromodulation of Mood Switch Circuitry in Bipolar Disorder (CircuitBD)
This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD.
Investigators in this study will use a technique called repetitive transcranial magnetic stimulation, or rTMS. It uses non-invasive magnetic pulses delivered to the scalp to stimulate specific areas of the brain. rTMS is already used to treat depression, and investigators are now studying whether it can be made even more effective for people with bipolar disorder by precisely targeting an individualized brain region for each participant. Participants in this study will receive two courses of rTMS, one active and one placebo (called "sham"), in a randomized order so investigators can directly compare the effects. Before treatment, investigators will use brain scans (MRI) to create a personalized map of each participant's brain activity. This lets investigators identify the exact stimulation target most likely to influence the brain circuits involved in BD mood shifts. Investigators will track mood symptoms closely throughout the study to measure what changes.
Investigators believe that depression in BD is partly driven by disrupted communication between two brain regions involved in processing what feels important or rewarding. Investigators want to find out whether rTMS can restore that communication and whether doing so leads to measurable improvements in depression.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Research Coordinator, Interventional Psychiatry Program
- Numero di telefono: 646-962-2900
- Email: tmsinfo@med.cornell.edu
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Weill Cornell Medicine
-
Contatto:
- Research Coordinator, Interventional Psychiatry Program
- Numero di telefono: 646-962-2900
- Email: tmsinfo@med.cornell.edu
-
Investigatore principale:
- Immanuel Elbau, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Adults of all genders aged 18-70 at the time of screening.
- Diagnosis of Bipolar Disorder (by DSM-V criteria)
- Depressive symptoms of at least moderate severity (GRID HDRS-17 score >= 14 or as determined by expert clinician).
- Not currently taking medications for BD OR on a stable dose of medication for at least 1 month prior to screening and plans to remain off medications OR on this stable dose for the duration of participation.
- Access to psychiatric care before, during, and after completion of the study.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
- Proficiency in English sufficient to complete assessments and follow study procedure instructions.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
Exclusion Criteria:
- Imminent risk of suicide.
- Presence of a primary DSM-5 diagnosis other than bipolar disorder (BD-I or BD-II), or a current comorbid psychiatric disorder that, in the opinion of the investigators, would confound outcome assessment or interfere with safe participation.
- History of seizures or any condition / concurrent medication that could notably lower seizure threshold.
- Met criteria for any significant substance use disorder (by DSM-V criteria) in the 6 months prior to screening.
- History or presence of significant neurological disorder (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy).
- History or presence of significant heart condition (e.g., recent myocardial infarction, congestive heart failure > stage 2, angina pectoris, bradycardia or tachycardia at the baseline assessment, uncontrolled hypertension).
- MRI contraindication, including presence of foreign metal bodies or implants, implanted or conductive objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), permanent make-up.
- Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation.
- Abnormal bloodwork for electrolytes, thyroid, or liver function.
- History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Active rTMS followed by Sham rTMS
Active rTMS administered during Intervention Phase 1; Sham rTMS (no active TMS pulses) administered during Intervention Phase 2. Participants will undergo two 5-day rTMS intervention phases (5 days of active stimulation followed by 5 days of sham stimulation) separated by a variable 4-12 week washout period.
|
TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting.
Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation.
The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation.
Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).
|
|
Sperimentale: Sham rTMS followed by Active rTMS
Sham rTMS (no active TMS pulses) administered during Intervention Phase 1; Active rTMS administered during Intervention Phase 2. Participants will undergo two 5-day rTMS intervention phases (5 days of sham stimulation followed by 5 days of active stimulation) separated by a variable 4-12 week washout period.
|
TANS-guided SAL Acc iTBS approach: Targeted Functional Network Stimulation (TANS) combines precision functional mapping (PFM) with electric field (E-field) modeling to individualize circuit targeting.
Active rTMS will be intermittent theta burst simulation (iTBS) delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly active rTMS sessions).
An Active/Placebo (A/P) sham TMS coil will be used to deliver placebo stimulation.
The A/P coil is a double-sided coil in which one side delivers effective magnetic stimulation, while the opposite side is configured to produce a sham condition without inducing cortical activation.
Sham stimulation will also be delivered to the salience network (SAL) with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly sham rTMS sessions).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline to 1-Week Post-rTMS in Montgomery-Asberg Depression Rating Scale (MADRS) Score
Lasso di tempo: Baseline to 1-week post-rTMS
|
Within-participant difference in change in depression, measured by score on the Montgomery-Asberg Depression Rating Scale (MADRS), in the active intervention phase vs. the sham intervention phase.
The minimum MADRS score is 0 and the maximum MADRS score is 60, with higher scores indicating greater depression severity.
The primary analysis uses a linear mixed-effects model with fixed effects for time (pre/post), condition (active/sham), intervention phase, and randomization sequence, with a subject-specific random intercept.
The primary endpoint is the time × condition interaction, reflecting differential symptom change for active versus sham rTMS.
|
Baseline to 1-week post-rTMS
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in salience network functional connectivity in active vs. sham rTMS
Lasso di tempo: Baseline to 1-week post-rTMS
|
Within-participant difference in change in salience network functional connectivity (FC) in the active intervention phase vs. the sham intervention phase.
Difference will be measured as pre-to-post rTMS change in FC between ventral striatum and anterior cingulate nodes of the salience network, with higher scores indicating greater FC.
The secondary analysis also uses a linear mixed-effects model with fixed effects for time (pre/post), condition (active/sham), intervention phase, and randomization sequence, with a subject-specific random intercept.
The primary endpoint is the time × condition interaction, reflecting differential change in FC for active versus sham rTMS.
|
Baseline to 1-week post-rTMS
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Immanuel Elbau, MD, PhD, Weill Medical College of Cornell University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 26-03029924
- TMI 250797-01 (Altro numero di sovvenzione/finanziamento: BD2 LLC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su fMRI
-
National Institute of Mental Health (NIMH)Reclutamento
-
University of MichiganNational Institute of General Medical Sciences (NIGMS)CompletatoAnestesia | Propofol | fMRIStati Uniti
-
University Hospital, GhentUniversity of Zurich; University GhentNon ancora reclutamento
-
Xidian UniversityReclutamentoVolontari sani | Ricerca fMRICina
-
Xidian UniversityReclutamentoVolontari sani | Neurofisiologia | Ricerca fMRICina
-
National Institute of Mental Health (NIMH)Reclutamento
-
National Institute of Mental Health (NIMH)ReclutamentofMRI | Lesione cerebrale focale | Lesioni focaliStati Uniti
-
University of California, San FranciscoNational Institute on Aging (NIA)Attivo, non reclutanteAdulti più anziani | Emozioni | Solitudine | Meditazione | fMRI | EEG | Intervento digitaleStati Uniti
-
University of Texas at AustinUniversity of Colorado, BoulderNon ancora reclutamentoAllenamento cognitivo | Neurofeedback | Memoria, a breve termine | Risonanza magnetica funzionale (fMRI)
-
Maastricht University Medical CenterWingate Institute of NeurogastroenterologyReclutamentofMRI | Stimolazione transcutanea del nervo vagale (tVNS) | Nucleo del tratto solitario (NTS)Olanda, Regno Unito
Prove cliniche su MagVenture MagPro TMS system
-
NeuroneticsReclutamentoDepressione | Disturbo ossessivo compulsivo | Ansia DepressioneStati Uniti
-
Mayo ClinicNational Institute of Mental Health (NIMH)ReclutamentoIdeazione suicida | Disturbo depressivo maggioreStati Uniti